Roche, Facing Biosimilar Threats, Puts Faith in New Cancer and Obesity Drugs

Why It Matters

The launch of giredestrant and obesity medicines is Roche’s primary hedge against a looming $8.6 billion revenue gap from biosimilars, shaping its future growth trajectory. Success would reposition Roche as a leader in two high‑growth therapeutic areas, offsetting declining cancer‑drug revenues.

Key Takeaways

• Roche aims $9 bn peak sales from giredestrant and obesity drugs
• Biosimilar competition could cut Swiss sales by $8.6 bn by 2030
• Analysts doubt giredestrant, forecasting only $1.5 bn peak sales
• Petrelintide could exceed $3 bn annual revenue in obesity market
• Roche expects mid‑single‑digit sales growth in 2026 despite currency dip

Pulse Analysis

Roche is navigating a pivotal crossroads as biosimilar entrants threaten to erode up to $8.6 billion of its cancer and immunology revenues by 2030. The Swiss giant’s 2026 outlook hinges on diversifying beyond its legacy biologics, with a strategic focus on high‑margin, late‑stage assets. By leveraging a robust pipeline, Roche hopes to sustain its mid‑single‑digit growth despite a 5% dip in first‑quarter earnings caused by a weaker U.S. dollar against the franc.

The breast‑cancer candidate giredestrant exemplifies Roche’s growth bet. Targeting ER‑positive, HER2‑negative tumors—a larger patient pool than Herceptin—giredestrant could become the company’s top seller if it clears the FDA by December 18. Yet recent setbacks in first‑line trials and Jefferies’ modest $1.5 billion peak‑sales forecast temper optimism. Roche’s dual submission strategy, including an adjuvant indication and a priority‑review voucher, reflects an aggressive push to secure market share before competing oral SERDs saturate the space.

Roche’s obesity franchise may prove the more lucrative engine. Petrelintide, licensed from Zealand Pharma, promises a differentiated side‑effect profile and oral convenience, positioning it against Lilly’s tirzepatide and Novo Nordisk’s semaglutide. The company projects the drug alone could surpass $3 bn in annual sales, with three additional candidates from the Carmot acquisition potentially adding another $3 bn. As global obesity rates climb toward 50% by 2035, Roche’s diversified approach could not only offset biosimilar losses but also cement its foothold in a market poised for double‑digit growth.